iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Sees Significant Growth in Short Interest

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 33,149 shares, a growth of 277.5% from the January 29th total of 8,781 shares. Based on an average trading volume of 48,195 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.7% of the shares of the company are short sold. Currently, 0.7% of the shares of the company are short sold. Based on an average trading volume of 48,195 shares, the days-to-cover ratio is currently 0.7 days.

iShares Genomics Immunology and Healthcare ETF Price Performance

iShares Genomics Immunology and Healthcare ETF stock traded down $0.62 during midday trading on Thursday, reaching $30.47. 11,013 shares of the company traded hands, compared to its average volume of 43,527. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $17.26 and a 12 month high of $31.39. The business has a 50 day moving average of $28.31 and a two-hundred day moving average of $25.79. The firm has a market capitalization of $152.35 million, a price-to-earnings ratio of 14.76 and a beta of 1.07.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

Institutional investors and hedge funds have recently modified their holdings of the company. Triumph Capital Management bought a new position in iShares Genomics Immunology and Healthcare ETF in the third quarter valued at about $35,000. Flow Traders U.S. LLC purchased a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 2nd quarter valued at about $931,000. Ameriprise Financial Inc. lifted its stake in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock worth $1,688,000 after purchasing an additional 5,540 shares during the period. Finally, Portland Global Advisors LLC bought a new position in shares of iShares Genomics Immunology and Healthcare ETF in the 2nd quarter worth approximately $2,099,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.